Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 4, 2021

Labcorp to acquire Myriad’s Vectra testing business for $150m

Labcorp has signed a definitive agreement to acquire certain operating assets and intellectual property (IP) of Myriad Genetics’ autoimmune business unit for $150m in cash.

Labcorp has signed a definitive agreement to acquire certain operating assets and intellectual property (IP) of Myriad Genetics’ autoimmune business unit for $150m in cash.

The acquisition includes the Vectra rheumatoid arthritis (RA) assay. The non-invasive blood test examines 12 biomarkers to check for RA disease activity.

The test merges these measures to create a simple score that signifies the severity of RA inflammation and indicates the success of existing therapies. It can also predict future joint damage.

More than one million Vectra tests have been performed since its introduction in November 2010 and a significant share of the testing volume is presently run through Labcorp.

The Vectra test and related IP, as well as other assets, are expected to merge well with Labcorp’s existing business activity focused on RA testing and treatment.

Labcorp diagnostics chief medical officer and president Brian Caveney said: “The addition of the Vectra testing capabilities to our in-house products offers tremendous potential for us to expand the test’s availability and make Labcorp a single-source diagnostics solution for RA providers.”

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

Subject to regulatory clearance and customary closing conditions, the acquisition is anticipated to conclude at the end of this year’s third quarter.

Myriad Genetics president and CEO Paul Diaz said: “While we are strong believers in the future growth prospects for Vectra, this divestiture will allow us to increase operational focus and better execute our core strategic businesses of women’s health, oncology and mental health.”

Hogan Lovells served as Labcorp’s legal adviser while Guggenheim Securities was the exclusive financial adviser for Myriad Genetics and Katten Muchin Rosenman acted as its legal adviser.

In February, Labcorp announced the availability of a new high-sensitivity antigen test to screen for active Covid-19 infection.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU